Dataset Information


Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells.

ABSTRACT: Chimeric antigen receptor modified T cells (CAR-T) therapy is an emerging immunotherapy against malignancies. However, only limited success was obtained in solid tumors. Polyinosinic-polycytidylic acid (poly I:C), ligand of TLR3, mediates innate immune and adaptive immune and shows broad antitumor effect on many types of cancer. In the present study, we combined EGFRvIII-targeted CAR-T cells with poly I:C treatment and evaluated the synergic antitumor effect in vitro and in immunocompetent mice bearing subcutaneous colon or orthotopic breast cancer xenografts. Poly I:C significantly promoted more IL-2 and IFN ? production as well as higher lytic activity of CAR-T cells. Upon systemic administration in vivo, CAR-T cells obviously suppressed tumor growth, and poly I:C significantly enhanced the suppression. Further study showed that poly I:C exerted antitumor effect dependent on type I IFNs. In addition, poly I:C decreased myeloid-derived suppressor cells (MDSC) number in peripheral blood and spleen, and attenuated the immunosuppressive activity of MDSC on proliferation and cytolytic function of CAR-T. Depletion of MDSC with anti-Gr1 Ab further increased the antitumor effect of CAR-T cells plus poly I:C treatment. In conclusion, CAR-T treatment combined with intratumoral delivery of poly I:C resulted in synergistic antitumor activity. We thus provide a rationale to translate this immunotherapeutic strategy to solid tumors.


PROVIDER: S-EPMC6481273 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7330669 | BioStudies
2014-01-01 | S-EPMC6741616 | BioStudies
2017-01-01 | S-EPMC5372296 | BioStudies
2018-01-01 | S-EPMC6033533 | BioStudies
2019-01-01 | S-EPMC6691897 | BioStudies
2012-01-01 | S-EPMC3472555 | BioStudies
2016-01-01 | S-EPMC5050151 | BioStudies
2017-01-01 | S-EPMC5695679 | BioStudies
2020-01-01 | S-EPMC7227242 | BioStudies
2015-01-01 | S-EPMC4467166 | BioStudies